Published in Herz on June 01, 1981
Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc Res (1999) 2.12
The effect of aortic valve replacement on survival. Circulation (1982) 2.03
L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation (2004) 1.85
Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation (1981) 1.68
Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol (1997) 1.60
Atrial fibrillation in dialysis patients. Nephrol Dial Transplant (2000) 1.54
Non-invasive assessment of perioperative myocardial cell damage by circulating cardiac troponin T. Br Heart J (1991) 1.46
Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. Cardiovasc Res (2000) 1.40
Ruptured aneurysms of the sinus of Valsalva. Ann Thorac Surg (1986) 1.34
Increase in myocardial Gi-proteins in heart failure. Lancet (1988) 1.33
Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am J Physiol (1993) 1.23
Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation (1984) 1.23
Positive inotropism of vanadate in cat papillary muscle. Nature (1978) 1.18
Quantitative morphologic findings of the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 1.16
Candida tropicalis Etr1p and Saccharomyces cerevisiae Ybr026p (Mrf1'p), 2-enoyl thioester reductases essential for mitochondrial respiratory competence. Mol Cell Biol (2001) 1.16
Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1. J Biol Chem (2000) 1.15
Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ Res (1991) 1.15
Alpha-1 adrenoceptor-mediated positive inotropic effect and inositol trisphosphate increase in mammalian heart. J Pharmacol Exp Ther (1988) 1.12
Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol (1996) 1.12
Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart (2002) 1.11
Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. J Mol Cell Cardiol (1999) 1.08
Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol (1995) 1.06
Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a role of cyclic AMP and cyclic GMP. J Pharmacol Exp Ther (1985) 1.04
Impact of atrio-biventricular pacing to poor left-ventricular function after CABG. Thorac Cardiovasc Surg (2002) 1.03
Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.02
INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation (2003) 1.01
Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation (1984) 1.01
Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ Res (1992) 1.01
Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol (1984) 1.00
Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther (1984) 1.00
Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor. J Pharmacol Exp Ther (1994) 0.98
Peroxisomal multifunctional enzyme of beta-oxidation metabolizing D-3-hydroxyacyl-CoA esters in rat liver: molecular cloning, expression and characterization. Biochem J (1997) 0.98
Regional expression of phospholamban in the human heart. Cardiovasc Res (1999) 0.98
[Lead-related complications in 340 patients with an implantable cardiverter/defibrillator]. Z Kardiol (1999) 0.98
Identification and characterization of diadenosine 5',5"'-P1,P2 -diphosphate and diadenosine 5',5"'-P1,P3-triphosphate in human myocardial tissue. FASEB J (1999) 0.97
Role of guanine nucleotide-binding protein in the regulation by adenosine of cardiac potassium conductance and force of contraction. Evaluation with pertussis toxin. Naunyn Schmiedebergs Arch Pharmacol (1986) 0.97
Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem (1996) 0.96
Mutagenic and enzymological studies of the hydratase and isomerase activities of 2-enoyl-CoA hydratase-1. Biochemistry (1999) 0.96
Adenosine inhibits the positive inotropic effect of 3-isobutyl-1-methylxanthine in papillary muscles without effect on cyclic AMP or cyclic GMP. Br J Pharmacol (1988) 0.95
Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts. Cardiovasc Res (1996) 0.93
Low seroprevalence of Helicobacter pylori infection in patients with stress ulcer bleeding--a prospective evaluation of patients on a cardiosurgical intensive care unit. Intensive Care Med (2000) 0.91
Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol (1996) 0.91
[Energy metabolism in the heart of uremic animals]. Verh Dtsch Ges Inn Med (1976) 0.90
Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovasc Res (2001) 0.90
Stimulatory effect of vanadate on (Na+ + K+)-ATPase activity and on 3H-ouabain-binding in a cat heart cell membrane preparation. Nature (1979) 0.90
Ca(++)-dependent constitutive nitric oxide synthase is not involved in the cyclic GMP-increasing effects of carbachol in ventricular cardiomyocytes. J Pharmacol Exp Ther (1993) 0.90
cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation (1995) 0.90
Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol (1992) 0.90
Insect vectors in serum hepatitis. Lancet (1972) 0.89
A study of 605 fatal pulmonary embolisms and two successful embolectomies. Surg Gynecol Obstet (1967) 0.89
Activation and inactivation of cAMP-response element-mediated gene transcription in cardiac myocytes. Cardiovasc Res (2001) 0.89
On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor. J Pharmacol Exp Ther (1995) 0.89
Heat shock protein 70 (HSP70) in gastric adaptation to aspirin in Helicobacter pylori infection. J Physiol Pharmacol (2001) 0.88
Survival and quality of life after a long-term intensive care stay. Thorac Cardiovasc Surg (2002) 0.88
Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr (1985) 0.88
Functional evidence for the existence of adenosine receptors in the human heart. Eur J Pharmacol (1985) 0.88
Regional expression of protein phosphatase type 1 and 2A catalytic subunit isoforms in the human heart. J Mol Cell Cardiol (2000) 0.88
Regional distribution of beta 1- and beta 2-adrenoceptors in the failing and nonfailing human heart. Eur J Clin Pharmacol (1992) 0.87
Cardiac alpha 1-adrenoceptor densities in different mammalian species. Br J Pharmacol (1992) 0.87
Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am J Physiol (1996) 0.87
Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol (1989) 0.86
In mouse alpha -methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. J Biol Chem (2000) 0.86
Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.86
Role of protein phosphatases in regulation of cardiac inotropy and relaxation. Am J Physiol Heart Circ Physiol (2001) 0.86
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.86
Isoprenaline stimulates gene transcription of the inhibitory G protein alpha-subunit Gi alpha-2 in rat heart. Circ Res (1993) 0.86
Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol (1994) 0.85
Evidence for adenosine receptor-mediated isoprenaline-antagonistic effects of the adenosine analogs PIA and NECA on force of contraction in guinea-pig atrial and ventricular cardiac preparations. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.85
Purified cardiac cell membranes with high (Na+ + K+)ATPase activity contain significant NADH-vanadate reductase activity. Nature (1979) 0.85
Long term beta-adrenoceptor-mediated up-regulation of Gi alpha and G(o) alpha mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart. Mol Pharmacol (1992) 0.85
Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int J Cardiol (1996) 0.84
Genetic disruption of G proteins, G(i2)alpha or G(o)alpha, does not abolish inotropic and chronotropic effects of stimulating muscarinic cholinoceptors in atrium. Br J Pharmacol (2009) 0.84
Quantitation of clobazam in human plasma using high-performance liquid chromatography. J Chromatogr Sci (1999) 0.84
Inhibition of the effects of adenosine on force of contraction and the slow calcium inward current by pertussis toxin is associated with myocardial lesions. Cardiovasc Res (1988) 0.84
Transcriptional regulation by cAMP in the heart. Mol Cell Biochem (2000) 0.84
Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther (1997) 0.84
Chronic treatment with carbachol sensitizes the myocardium to cAMP-induced arrhythmia. Circulation (1996) 0.84
Effect of 2,3-butanedione monoxime on force of contraction and protein phosphorylation in bovine smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (1999) 0.83
Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol (1996) 0.83
Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol (1996) 0.83
Inorganic phosphate inhibits contractility and ATPase activity in skinned fibers from human myocardium. Basic Res Cardiol (1990) 0.83
Long-term beta adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca(++)-ATPase in mammalian ventricle. J Pharmacol Exp Ther (1998) 0.83
Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Br J Pharmacol (1992) 0.83
Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol (1991) 0.83
Isoprenaline-induced increase in mRNA levels of inhibitory G-protein alpha-subunits in rat heart. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.83
Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.82
Increase in IP3 precedes alpha-adrenoceptor-induced increase in force of contraction in cardiac muscle. Eur J Pharmacol (1987) 0.82
In vivo beta-adrenergic stimulation leads to biphasic regulation of Gi alpha-2 gene transcriptional activity in rat heart. J Mol Cell Cardiol (1994) 0.82
Interaction of beta-adrenoceptor and adenosine receptor agonists on phosphorylation. Identification of target proteins in mammalian ventricles. J Mol Cell Cardiol (1995) 0.82
Amphetamine, cocaine and cannabinoids use among truck drivers on the roads in the State of Sao Paulo, Brazil. Forensic Sci Int (2011) 0.82
Increased responsiveness to stimulation of alpha- but not beta-adrenoceptors in the hereditary cardiomyopathy of the Syrian hamster. Intact adenosine- and cholinoceptor-mediated isoprenaline antagonistic effect. Eur J Pharmacol (1986) 0.82
Distinct down-regulation of cardiac beta 1- and beta 2-adrenoceptors in different human heart diseases. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.82
Postnatal changes in contractile time parameters, calcium regulatory proteins, and phosphatases. Am J Physiol (1998) 0.82
CREB critically regulates action potential shape and duration in the adult mouse ventricle. Am J Physiol Heart Circ Physiol (2012) 0.82
Molecular aspects of adrenergic signal transduction in cardiac failure. J Mol Med (Berl) (1998) 0.82
Pertussis toxin does not inhibit the alpha 1-adrenoceptor-mediated effect on inositol phosphate production in the heart. Eur J Pharmacol (1987) 0.82